Latest research on Sunitinib

Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.

Latest findings

After a preliminary screening study, we choose 3 target TKI drugs, including Erlotinib hydrochloride, Afatinib, and Sunitinib. [source, 2016]
Sunitinib is an oral, small-molecule, multi-targeted receptor TYROSINE kinase (RTK) inhibitor that was approved to treat renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumors [20]. [source, 2016]
Dimethyl sulfoxide (DMSO), pyrimethamine, and Sunitinib malate (SU 11248) were purchased from Sigma Aldrich (St. Louis, Missouri, USA). [source, 2016]
The concentrations of Afatinib, Erlotinib, and Sunitinib were 10, 50, and 10 µM, respectively (Fig. 1). [source, 2016]
These results showed that Afatinib 10 µM completely inhibited the intracellular growth of T. gondii similar to the inhibitory effect of pyrimethamine 5 µM, whereas Erlotinib 50 µM and Sunitinib 10 µM did not inhibit the intracellular growth of the parasite. [source, 2016]
Recent results of most molecular targeted agents are disappointing; however, Sunitinib [13] and erverolimus [14] showed verified activities in a phase II study. [source, 2016]
Based on c-Kit gene mutant status, drugs that inhibit c-Kit, such as Imatinib [39], sorafenib [40], and Sunitinib [41], may provide better results [42]. [source, 2016]
However, Sunitinib, and everolimus for refractory thymic carcinoma, and cixutumumab for refractory thymoma have an anticipated clinical benefit in phase II studies. [source, 2016]
Sunitinib is a promising agent with the biological plausibility of inhibition for c-Kit and antiangiogenic effects [41]. [source, 2016]
Calculating from the results of median PFS from phase II trials of Sunitinib, everolimus, and the present retrospective study of S-1 for thymic carcinoma, a total of 7.2 months of Sunitinib treatment costs about 30,000 EUR (5,700 EUR per each cycle (6 weeks)), and a total of 12.1 months of everolimus treatment costs 68,500 EUR (7,300 EUR per 6 weeks), and a total of 8.1 months of S-1 treatment costs 4,200 EUR (700 EUR per cycle (6 weeks)). [source, 2016]